Acadia Pharmaceuticals | ACAD - 资产



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 4.29B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


资产 更改 日
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Cara Therapeutics USD 32.07M 6.95M 2025-12
Corcept Therapeutics USD 814.88M 21.77M 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Incyte USD 7.34B 381.14M 2026-03
J&J USD 200.89B 1.68B 2026-03
Moderna USD 11.49B 850M 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pfizer USD 207.62B 542M 2026-03
Prothena USD 349.89M 23.09M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03